Patents by Inventor Nalin Subasinghe

Nalin Subasinghe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzo-fused heterocyclic derivatives useful as agonists of GPR120
    Patent number: 10155737
    Abstract: The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: December 18, 2018
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Zhihua Sui, Nalin Subasinghe
  • BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120
    Publication number: 20170088531
    Abstract: The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
    Type: Application
    Filed: December 8, 2016
    Publication date: March 30, 2017
    Inventors: Zhihua Sui, Nalin Subasinghe
  • Benzo-fused heterocyclic derivatives useful as agonists of GPR120
    Patent number: 9562053
    Abstract: The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: February 7, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Zhihua Sui, Nalin Subasinghe
  • Substituted pyrazoles as N-type calcium channel blockers
    Patent number: 9434693
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R1, R2, ring A, and G are defined herein.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: September 6, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Wall, Nalin Subasinghe, Zhihua Sui, Christopher Flores
  • Cyclohexyl-azetidinyl antagonists of CCR2
    Patent number: 9062048
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: June 23, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui
  • 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2
    Patent number: 8921559
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: December 30, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui, Xuqing Zhang
  • Substituted pyrazoles as N-type calcium channel blockers
    Patent number: 8901314
    Abstract: The present invention relates to compounds of Formula (I), wherein X1, X2, X3, X4, R1, R2, R3, and Q are as defined herein, useful as N-type calcium channel blockers.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: December 2, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Wall, Nalin Subasinghe, Zhihua Sui, Christopher Flores
  • BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120
    Publication number: 20140275172
    Abstract: The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Zhihua Sui, Nalin Subasinghe
  • SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS
    Publication number: 20140163031
    Abstract: The present invention relates to compounds of Formula (I), wherein X1, X2, X3, X4, R1, R2, R3, and Q are as defined herein, useful as N-type calcium channel blockers.
    Type: Application
    Filed: August 16, 2013
    Publication date: June 12, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark Wall, Nalin Subasinghe, Zhihua Sui
  • SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS
    Publication number: 20140162997
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R1, R2, ring A, and G are defined herein.
    Type: Application
    Filed: August 16, 2013
    Publication date: June 12, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark Wall, Nalin Subasinghe, Zhihua Sui, Christopher Flores
  • CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
    Publication number: 20130310365
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: July 22, 2013
    Publication date: November 21, 2013
    Applicant: Janssen Pharmaceutical NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui
  • Cyclohexyl-azetidinyl antagonists of CCR2
    Patent number: 8518969
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: August 27, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui
  • 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2
    Publication number: 20120142733
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Application
    Filed: November 30, 2011
    Publication date: June 7, 2012
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui, Xuqing Zhang
  • CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
    Publication number: 20110312936
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 16, 2011
    Publication date: December 22, 2011
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui
  • Conjugated complement cascade inhibitors
    Patent number: 7482376
    Abstract: The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.
    Type: Grant
    Filed: June 16, 2004
    Date of Patent: January 27, 2009
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Nalin Subasinghe, Ehab Khalil, Farah Ali, Heather Rae Hufnagel, Shelley Ballentine, Jeremy M. Travins, Kristi A. Leonard, Roger F. Bone
  • Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions
    Publication number: 20070066667
    Abstract: Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. Said compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are defined in the specification, as are A Z, Q, R1 and R2.
    Type: Application
    Filed: March 14, 2006
    Publication date: March 22, 2007
    Inventors: Nalin Subasinghe, Shelley Ballentine, Jeremy Travins, Ehab Khalil, Farah Ali, Kristi Leonard, Joan Gushue, Michael Winters, Heather Hufnagel, Maxwell Cummings
  • Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
    Patent number: 7138530
    Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: November 21, 2006
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Nalin Subasinghe, Ehab Khalil, Kristi A. Leonard, Farah Ali, Heather Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, Jonathan M. Rudolph, Hui Huang
  • Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
    Patent number: 7109354
    Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: September 19, 2006
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M. Jonathan Rudolph, Hui Huang
  • Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
    Publication number: 20050234081
    Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.
    Type: Application
    Filed: May 28, 2003
    Publication date: October 20, 2005
    Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Hufnagel, Jeremy Travins, Shelley Ballentine, Kenneth Wilson, Maxwell Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen
  • Conjugated complement cascade inhibitors
    Publication number: 20050004031
    Abstract: The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.
    Type: Application
    Filed: June 16, 2004
    Publication date: January 6, 2005
    Inventors: Nalin Subasinghe, Ehab Khalil, Farah Ali, Heather Hufnagel, Shelley Ballentine, Jeremy Travins, Kristi Leonard, Roger Bone